Methods to detect tumors using 20P1F12/TMPRSS2 expression

Details Methods to detect tumors using 20P1F12/TMPRSS2 expression Methods to detect tumors using 20P1F12/TMPRSS2 expression

2011-07-19

2011-07-19

Goddard, Laura B (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

Reexamination Certificate

active

07981624

ABSTRACT:
Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG.1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth. The invention further provides various therapeutic compositions and strategies for treating prostate cancer, including particularly, 20P1F12/TMPRSS2 polypeptide and anti-20P1F12/TMPRSS2 antibody therapy methods and compositions, cancer vaccines, and small molecule therapy.

REFERENCES:
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 6043033 (2000-03-01), Bandman et al.
patent: 6166194 (2000-12-01), Wong et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 6294663 (2001-09-01), O'Brien et al.
patent: 6331427 (2001-12-01), Robison
patent: 6350448 (2002-02-01), Bandman et al.
patent: 6500938 (2002-12-01), Au-Young et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0081580 (2002-06-01), Xu et al.
patent: 2002/0090372 (2002-07-01), Xu et al.
patent: 2002/0119531 (2002-08-01), Bandman et al.
patent: 2002/0160382 (2002-10-01), Lasek et al.
patent: 2002/0192763 (2002-12-01), Xu et al.
patent: 2003/0065157 (2003-04-01), Lasek
patent: 2003/0103981 (2003-06-01), Spancake et al.
patent: 2006/0275304 (2006-12-01), Afar et al.
patent: 1368509 (2002-09-01), None
patent: 1 033 401 (2000-09-01), None
patent: WO-93/01309 (1993-01-01), None
patent: WO-94/16083 (1994-07-01), None
patent: WO-98/37093 (1998-08-01), None
patent: WO-98/37418 (1998-08-01), None
patent: WO-99/62942 (1999-12-01), None
patent: WO-00/00605 (2000-01-01), None
patent: WO-00/04149 (2000-01-01), None
patent: WO-00/12758 (2000-03-01), None
patent: WO-00/18961 (2000-04-01), None
patent: WO-00/23111 (2000-04-01), None
patent: WO-00/55351 (2000-09-01), None
patent: WO-00/65067 (2000-11-01), None
patent: WO-01/22920 (2001-04-01), None
patent: WO-01/25272 (2001-04-01), None
patent: WO-01/34802 (2001-05-01), None
patent: WO-01/40276 (2001-06-01), None
patent: WO-01/51633 (2001-07-01), None
patent: WO-01/57194 (2001-08-01), None
patent: WO-01/60860 (2001-08-01), None
patent: WO-01/73032 (2001-10-01), None
patent: WO-01/96538 (2001-12-01), None
patent: WO-02/04953 (2002-01-01), None
patent: WO-02/30268 (2002-04-01), None
patent: WO-02/089747 (2002-11-01), None
patent: WO-02/095007 (2002-11-01), None
patent: WO-03/003906 (2003-01-01), None
patent: WO-03/009814 (2003-02-01), None
Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25).
Zellner et al (Clin. Can. Res., 1998, 4:1797-17802).
Slamon et al, (Cancer Cells, 1989, 7:371-384).
Stein et al (Cancer Research, Apr. 2004, 64:2805-2816).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Kultima et al (BMC Bioinformatics, 2006, 7:475, internet pp. 1-27).
Sambrook et al. (Molecular Cloning, 2nd edition, Cold Spring Harbor Press, 1989, p. 18.47).
Invitrogen™ product information sheet, printed Jan. 3, 2008, 4 pages.
Afar et al., (2001). “Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia,” Cancer Res. 61(4):1686-1692.
Albini, Pathology Oncology Research (1998) 4(3):230-241.
Amalfitano et al., Current Gene Therapy (2002) 2:111-133.
Bellone et al., (1999). “Cancer Immunotherapy: Synthetic and Natural Peptides in the Balance” Immunology Today 20(10):457-462.
Bowie et al., (1990). Science 257:1306-1310.
Burgess et al., (1990). Journal of Cell Bio. 111:2129-2138.
Christiansen et al., Mol. Cancer Ther. (2004) 3:1493-1501.
Database EMBL Nucleotide and Protein Sequences; Mar. 11, 1997; Hinxton, GB; AC=AA244195.Homo sapienscDNA Clone Image: 1007327 Similar to SW:KAL-RAT P14272 Plasma Kallikrein Precursor. Est. [Abstract].
Database EMBL Nucleotide and Protein Sequences; May 20, 1997; Hinxton, GB; AC=AA423272.Mus musculuscDNA Clone 820366 5′ Similar to SW:KAL-Human P03952 Plasma Kallikrein Precursor Est. [Abstract].
Database EMBL Nucleotide and Protein Sequences; Nov. 16, 1998, Hinxton, GB AC=A1261741.Homo sapienscDNA Clone Image:2028487 3′ DE Similar to TR:015393 015393 Serine Protease.; mRNA Sequence [Abstract].
Fair et al., (1997). “Prostate-Specific Membrane Antigen” Prostate 32(2):140-148.
Gaiger et al., (2000). “Immunity to WT1 in tha Animal Model and in Patients with Acute Myloid Leukemia” Blood 96(4):1480-1489.
Gura, (1997). “Systems for Identifying New Drugs Are Often Faulty” Science 278:1041-1042.
Hazan et al., The Journal of Cell Biology (2000) 148(4):779-790.
Hessels et al., (2004). “Applicability of biomarkers in the early diagnosis of prostate cancer,” Expert Rev. Mol. Diagn. 4(4):513-526.
Hildmann et al., (1999). “A Contiguous 3-Mb Sequence-Ready Map in the S3-MX Region on 21q22.2 Based on High-Throughput Nonisotopic Library Screenings” Genome Research 9:360-372.
Lazar et al., (1988). Molecular and Cellular Biology 8:1247-1252.
Lin et al., (1999). “Prostate-Localized and Androgen-Regulated Expression of the Membrane-Bound Serine Protease TMPRSS21” Cancer Research 59:4180-4184.
McCormick, Nature Reviews (2001) 1:130-141.
McNeish et al., Gene Therapy (2004) 11:497-503.
Meibohm, Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VHC (2006) Chapter 3, pp. 45-91 and contents IX-XVII.
Office Action for Japanese Patent Application No. 2002-509772, mailed on Aug. 27, 2008, 5 pages.
Pandha et al., Current Opinion in Investigational Drugs (2000) 1(1):122-134.
Paoloni-Giacobino et al., (Sep. 2001). “Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane , LDLRA, and SRCR Domains and Maps to 21q22.3” Genomics Erratum 77(1/2):114.
Paoloni-Giacobino et al., (1997). “Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane , LDLRA, and SRCR Domains and Maps to 21q22.3” Genomics 44(3):309-320.
Reiger et al., (1976).Glossary of Genetics and Cytogenetics, Classical and Molecular4thEd., Springer-Verlay. Berlin pp. 17-18.
Sequence search 20070125—090904—us-11-147-804-2.rai; result No. 1, p. 1-6.
Sinha et al., Anticancer Research (1998) 18(3A):1385-1392.
Sinha et al., Anticancer Research (1999) 19:893-902.
Tanimoto et al., (1997). “Hepsin, A Cell Surface Serine Protease Identified in Hepatoma Cells, Is Overexpressed in Ovarian Cancer” Cancer Research 57(14):2884-2887.
Topp et al., Journal of Controlled Release (1998) 53:15-23.
Vaarala et al., (2001). “The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease,” Int. J. Cancer 94(5):705-710.
Verma et al., Nature (1997) 389:239-242.
Weiner, (1999). “An Overview of Monoclonal Antibody Therapy of Cancer” Seminars in Oncology 26(4):41-50.
Welt et al., J. of Clinical Oncology (1996) 14:1787-1797.
Wong et al., (Jun. 1998). Sequence Comparison, USPTO Protein Database.
Xing and Rabbani, Endocrinology (2007) 140(9):4056-4064.
Yamamoto et al., (1997). “Raised Prostate-Specific Antigen in Adenocarcinoma of the Colon” International Urology and Nephrology 29(2):221-225.
Young et al., (1995). “Expression and Androgenic Regulation of Human Prostate-Specific Kallikreins” J

Affiliated with

Also associated with

Rating

Methods to detect tumors using 20P1F12/TMPRSS2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to detect tumors using 20P1F12/TMPRSS2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to detect tumors using 20P1F12/TMPRSS2 expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2717600